Monopar Therapeutics Inc. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets
Monopar Therapeutics Inc. (MNPR) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets of $18.50 million as of 2018-12-31, per its 10-K filed 2019-02-26.
Discontinued › Notes › Business Combination, Recognized Asset Acquired, Asset
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets · last filed 2019-02-26
- 2018-12-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets $18.50M.
- 2017-12-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets $18.50M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets |
|---|---|
| 2018-12-31 | $18.50M 10-K · filed 2019-02-26 |
| 2017-12-31 | $18.50M 10-K · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |